Eagle Pharmaceuticals Inc (NAS:EGRX)
$ 3.8 0.34 (9.8%) Market Cap: 49.24 Mil Enterprise Value: 105.50 Mil PE Ratio: 4.18 PB Ratio: 0.20 GF Score: 62/100

Q3 2020 Eagle Pharmaceuticals Inc Earnings Call Transcript

Nov 02, 2020 / 01:30PM GMT
Release Date Price: $49.22 (+5.80%)
Operator

Good morning, everyone. My name is Reid, and I'll be your conference operator. At this time, I'd like to welcome everyone to Eagle Pharmaceuticals' Third Quarter 2020 Earnings Results Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded today, November 2, 2020.

It is now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. Please go ahead.

Lisa Wilson;In;Site Communications

Thank you, Reid. Welcome to Eagle Pharmaceuticals Third Quarter Earnings Call. This is Lisa Wilson, Investor Relations for Eagle Pharmaceuticals.

With me on today's call are Eagle's Chief Executive Officer, Scott Tarriff; David Pernock, President and Chief Operating Officer; and our newly appointed Chief Financial Officer, Brian Cahill.

This morning, the company issued a press release detailing financial results for the 3 months ended September 30, 2020. This press release and a webcast of this call can be accessed through the Investors section of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot